Matrifen

Fentanyl, the active ingredient in Matrifen, is an opioid analgesic presented as a transdermal patch for transdermal use. It provides continuous systemic delivery of opioid medication for the management of chronic severe pain, including cancer‑related pain and persistent non‑cancer pain, in patients who require around‑the‑clock analgesia. The patch is designed for once‑weekly application, allowing steady plasma concentrations and reducing the need for frequent dosing.

GNH USA supplies Matrifen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Fentanyl is an opioid analgesic used in the management of severe, persistent pain conditions. - Chronic severe cancer pain: provides continuous opioid analgesia to reduce breakthrough pain episodes. - Chronic non‑cancer pain: delivers steady opioid levels for patients with pain unresponsive to other therapies. - Post‑operative pain (when indicated): may be used for ongoing analgesia after major surgery when oral opioids are insufficient.

Fentanyl transdermal therapy can be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Constipation: reduced bowel movements. - Dizziness: light‑headed sensation. - Local skin irritation: redness or itching at the patch site.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing that can be life‑threatening. - Severe hypotension: marked drop in blood pressure. - Opioid dependence or withdrawal: signs of addiction or withdrawal upon abrupt discontinuation.

When prescribing or using Matrifen, several safety considerations should be observed to minimize risk. - Assess patient suitability: confirm opioid tolerance and evaluate pain severity. - Avoid use in patients with significant respiratory disease: risk of respiratory depression. - Monitor for signs of sedation or confusion: especially during dose titration. - Do not apply to damaged or inflamed skin: may affect drug absorption. - Concomitant CNS depressants: use with caution as they can enhance sedation. - Store at room temperature: keep patches in original packaging, protect from moisture and direct sunlight.

Fentanyl may interact with other medications, altering its effect or increasing adverse events.

Major Interactions (Avoid): - Benzodiazepines or other CNS depressants: can cause profound respiratory depression. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase fentanyl plasma levels, risk of toxicity. - MAO inhibitors: may precipitate severe hypotension or serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce fentanyl efficacy. - Anticholinergic agents: can exacerbate constipation. - Alcohol: additive CNS depression, requires careful monitoring.